Chevy Chase Trust Holdings LLC Boosts Holdings in Agilent Technologies, Inc. $A

Chevy Chase Trust Holdings LLC boosted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 0.6% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 152,236 shares of the medical research company’s stock after buying an additional 868 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Agilent Technologies were worth $17,965,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Generation Investment Management LLP boosted its stake in shares of Agilent Technologies by 19.8% during the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after purchasing an additional 824,243 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Agilent Technologies by 18.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after purchasing an additional 604,124 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Agilent Technologies by 141.5% during the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after purchasing an additional 548,344 shares during the period. Woodline Partners LP boosted its stake in shares of Agilent Technologies by 681.6% during the first quarter. Woodline Partners LP now owns 522,073 shares of the medical research company’s stock valued at $61,072,000 after purchasing an additional 455,276 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Agilent Technologies by 16.2% during the second quarter. Nordea Investment Management AB now owns 3,213,748 shares of the medical research company’s stock valued at $383,143,000 after purchasing an additional 447,207 shares during the period.

Analyst Upgrades and Downgrades

A has been the subject of a number of recent analyst reports. Robert W. Baird boosted their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Barclays lifted their price objective on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Evercore ISI lifted their price objective on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. Wells Fargo & Company lifted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, September 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $149.62.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $142.01 on Friday. The company has a market capitalization of $40.26 billion, a PE ratio of 33.34, a P/E/G ratio of 4.63 and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The company has a 50-day simple moving average of $127.58 and a two-hundred day simple moving average of $117.84. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm’s revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.248 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. Agilent Technologies’s payout ratio is presently 23.24%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.